代表性成果
代表性项目/课题
1、广州医科大学2024年科研能力提升计划重大临床研究项目培育项目，GMUCR2024-02017，广州呼研院哮喘患者在线登记数据库系统建设，主持，2024-4至2027
2、国家自然科学基金面上项目，82270035，感觉神经环路及TRPA1在变应性鼻炎相关咳嗽高敏感性中的作用及机制研究，主持，53万，2023-01至2025-12
3、广州市科技局，市校（院）联合资助项目，异位淋巴组织介导的气道自身免疫在重症嗜酸粒细胞型哮喘发病机制的作用，2022-01至2022-12，25万元，主持
4、广东省科技厅，创新项目，新型冠状病毒肺炎与慢性阻塞性肺疾病的多中心回顾性研究，2020-05至2020-12，2020B1111340019，10万元，主持
5、国家自然科学基金委员会，青年科学基金项目，81100028，TRPV1和TRPA1在变应性鼻炎继发下气道炎症及高反应性中的作用，2012-01至2014-12，23万元，结题，主持
代表性论文
1、谢佳星#,徐镶怀,余莉,等. 慢性咳嗽年度进展2025[J]. 中华结核和呼吸杂志,2026,49(04)：434-442.DOI:10.3760/cma.j.cn112147-20251217-00801
2、Chen Y, Xie J*. Severe Dry Cough Followed by Eosinophilia Without Pulmonary Infiltrates After Dupilumab Treatment in Patients with Severe Asthma: A Series of Five Cases. J Inflamm Res. 2025 Dec 17;18:17759-17768. doi: 10.2147/JIR.S545661. PMID: 41439127; PMCID: PMC12719626.
3、Fang ZF, Fu Y, Yi F, Chen Z, Li YZ, Wang ZN, Dong JY, Yang PC, Xu D*, Liu XY*, Xie JX*. Neural control of the pathophysiology of allergic airway disease and its clinical implications: A focus on allergic rhinitis and asthma. J Allergy Clin Immunol. 2025 Aug;156(2):259-269. doi: 10.1016/j.jaci.2025.05.017. Epub 2025 May 28. PMID: 40447196.
4、Changxing Ou et al. Qingling Zhang*, Jiaxing Xie*, on behalf of the C-BIOPRED Consortium. C-BIOPRED severe asthma clinical phenotypes: link to complement and coagulation pathways and galectin 10. ERJ Open Research 2025 01016-2024;
5、Chen Y, Wang L, Xie J*. Combining Dual Biologics Therapy for Severe Asthma: A Series of Ten Cases. J Asthma Allergy. 2025 Apr 5;18:507-517.
6、谢佳星#，赖克方.咳嗽频率监测及其临床研究应用.中华结核和呼吸杂志. 2025, DOI: 10.3760/cma.j.cn112147-20250313-00139.
7、李锡容, 谢佳星*.度普利尤单抗诱导重度哮喘患者血液嗜酸性粒细胞增多研究进展[J].中国呼吸与危重监护杂志, 2025, 24(2):140-146.
8、Fang ZF, Wang ZN, Chen Z, Peng Y, Fu Y, Yang Y, Han HL, Teng YB, Zhou W, Xu D, Liu XY, Xie JX*, Zhang JJ*, Zhong NS*. Fine particulate matter contributes to COPD-like pathophysiology: experimental evidence from rats exposed to diesel exhaust particles. Respir Res. 2024 Jan 4;25(1):14. doi:10.1186/s12931-023-02623-y. PMID: 38178075; PMCID: PMC10765838.
9、Li Y, Deng Z, Wen J, Ou C, Cen X, Liao Y, Zhang Q*, Xie J*. Efficacy of dupilumab and risk factors for dupilumab-induced hypereosinophilia in severe asthma: a preliminary study from China. Ann Med. 2024 Dec;56(1):2311843. doi:10.1080/07853890.2024.2311843. Epub 2024 Feb 5. PMID: 38316016; PMCID:PMC10846423.
10、李游,林慧敏,张筱娴,欧昌星,谢佳星*,张清玲. 度普利尤单抗治疗重度哮喘初步疗效的临床观察研究. 中华结核和呼吸杂志.12 Sep 2023, Vol. 46, Issue 9, pages 909 – 915
11、Chen B, Rong Q, Fu Y, Liang H, Kong X, Zhang Q, Jiang M*, Wang Z*, Xie J*. Characteristics of patients with incidental eosinophilia admitted to a tertiary hospital in southern China. Heliyon. 2023 Apr 20;9(5):e15569. doi:10.1016/j.heliyon.2023.e15569. PMID: 37144198
12、Qin R#, An J#, Xie J#(共同第一作者), Huang R, Xie Y, He L, Xv H, Qian G, Li J*. FEF25-75% Is a More Sensitive Measure Reflecting Airway Dysfunction in Patients with Asthma: A Comparison Study Using FEF25-75% and FEV1. J Allergy Clin Immunol Pract. 2021 Jun 30:S2213-2198(21)00715-7. doi: 10.1016/j.jaip.2021.06.027. Epub ahead of print.PMID: 34214706.
13、Xie J#, Chung KF, Lai K*. Uncommon causes of chronic cough associated with airway eosinophilia. J Thorac Dis 2021. doi: 10.21037/jtd-20-2324
14、Zhangfu Fang, Fang Yi, Yang Peng, Kefang Lai*, Jiaxing Xie*. Inhibition of TRPA1 reduces airway inflammation and hyperresponsiveness in mice with allergic rhinitis. The FASEB Journal. 2021, 35(5), e21428. doi:10.1096/fj.201902627R
15、Xie J#, Zhang J, Zhang X, Zhang Q, Chung KF, Wang C, Lai K*. Cough in hypereosinophilic syndrome: case report and literature review. BMC Pulm Med. 2020 Apr 15;20(1):90. doi: 10.1186/s12890-020-1134-x
16.、Qiu R#，Xie J# (共同第一作者)，Chung KF，Li N，Yang Z，He M，Li J，Chen R，Zhong N，Zhang Q*. Asthma Phenotypes Defined From Parameters Obtained During Recovery From a Hospital-Treated Exacerbation. J Allergy Clin Immunol Pract. 2018 Mar 1. pii: S2213-2198(18)30104-1
代表性专著
1、谢佳星，李靖，张清玲主编，《肺部嗜酸性粒细胞浸润相关疾病鉴别诊断》，人民卫生出版社，2021。
2、赖克方主编，刘辉国，张旻，罗炜，黄克武，谢佳星副主编，《中国哮喘标准术语集》，中国医药科技出版社，2025。
吴红玲
